New York Mets owner and billionaire investor Steve Cohen is renowned for his high-risk, high-reward investing style. He founded SAC Capital Advisors—once among the most successful hedge funds—before establishing Point72 Asset Management. With a net worth estimated at $23 billion (£17 billion), Cohen's hedge fund has delivered impressive gains over recent years, outperforming the broader market. Over the past three years, Point72's top 20 holdings have gained 131%, compared to the 64% rise in the S&P 500.
On 29th December 2025, Point72 added Tonix Pharmaceuticals (Nasdaq: TNXP) to its portfolio, purchasing over 1.23 million shares of the biotech stock worth approximately $20 million (£14.9 million), at an average price of $16.28 (£12.09) per share. The company has announced several significant milestones in the past month, which investors are viewing as positive catalysts for the stock.
